• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by American Well Corporation

    11/4/24 9:00:52 AM ET
    $AMWL
    Real Estate
    Real Estate
    Get the next $AMWL alert in real time by email
    S-8 1 dp220265_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on November 4, 2024

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    AMERICAN WELL CORPORATION

    (Exact Name of Registrant as Specified in its Charter)

     

    Delaware 7372 20-5009396
    (State or Other Jurisdiction of
    Incorporation or Organization)
    (Primary Standard Industrial Classification Code Number) (I.R.S. Employer
    Identification No.)
     

    75 State Street, 26th Floor

    Boston, MA 02109

     

    (Address of Principal Executive Offices)

     

     

     

    American Well Corporation 2024 Inducement Plan

    (Full Titles of the Plans)

     

    Ido Schoenberg

    Chief Executive Officer

    American Well Corporation

    75 State Street, 26th Floor

    Boston, MA 02109

    (617) 204-3500 

    (Name, Address, Including Zip Code, and Telephone Number,

    Including Area Code, of Agent For Service)

     

     

     

    With copies to:

    Adam Kaminsky

    Michael Kaplan
    Davis Polk & Wardwell LLP
    450 Lexington Avenue
    New York, New York 10017
    (212) 450-4000

     

    Bradford Gay

    SVP, General Counsel
    American Well Corporation

    75 State Street, 26th Floor

    Boston, MA 02109

    (617) 204-3500 

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer, ” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☒
    Non-accelerated filer ☐ (Do not check if a smaller reporting company) Smaller reporting company ☐
      Emerging Growth Company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

    1 

     

    EXPLANATORY NOTE

     

    The information specified in Part I of Form S-8 is omitted from this filing in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the introductory note to Part I of the Form S-8 instructions. The documents containing the information specified in Part I will be delivered to the participants in the American Well Corporation 2024 Inducement Plan (the “Inducement Plan”), as specified by Rule 428(b)(1) under the Securities Act.

     

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by American Well Corporation (the “Registrant”) with the Securities and Exchange Commission (the “Commission”) under the Securities Act or the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:

     

    (a)The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by the Registrant with the Commission on February 15, 2024, as amended pursuant to that Amendment No. 1 on Form 10-K/A to the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by the Registrant on March 1, 2024, which contain the Registrant’s audited financial statements for the latest fiscal year for which such statements have been filed;

     

    (b)The Registrant’s Quarterly Reports on Form 10-Q for the quarter ended March 31, 2024, filed with the Commission on May 1, 2024, the quarter ended June 30, 2024, filed with the Commission on July 31, 2024 and the quarter ended September 30, 2024, filed with the Commission on October 30, 2024;

     

    (c)The Registrant’s Current Reports on Form 8-K, filed with the Commission on each of April 4, 2024, June 13, 2024, June 24, 2024, July 1, 2024, July 16, 2024, August 22, 2024 and October 15, 2024; and

     

    (d)The description of the Registrant’s securities included in Exhibit 4.7 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

     

    In addition, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than documents or any information therein deemed to have been furnished and not filed in accordance with rules of the Commission), prior to the filing of a post-effective amendment to this Registration Statement on Form S-8 (the “Registration Statement”), which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein (or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein), modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    2 

     

    Item 6. Indemnification of Directors and Officers.

     

    Section 145 of the Delaware General Corporation Law provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any threatened, pending or completed actions, suits or proceedings in which such person is made a party by reason of such person being or having been a director, officer, employee or agent to the Registrant. The Delaware General Corporation Law provides that Section 145 is not exclusive of other rights to which those seeking indemnification may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise. Article 9 of the Registrant’s certificate of incorporation provides for indemnification by the Registrant of its directors, officers and employees to the fullest extent permitted by the Delaware General Corporation Law. The Registrant has entered into indemnification agreements with each of its current directors and executive officers to provide these directors and executive officers additional contractual assurances regarding the scope of the indemnification set forth in the Registrant’s amended and restated certificate of incorporation and amended and restated bylaws and to provide additional procedural protections. There is no pending litigation or proceeding involving a director or executive officer of the Registrant for which indemnification is sought.

     

    Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) for unlawful payments of dividends or unlawful stock repurchases, redemptions or other distributions, or (iv) for any transaction from which the director derived an improper personal benefit. The Registrant’s certificate of incorporation provides for such limitation of liability.

     

    The Registrant maintains standard policies of insurance under which coverage is provided (a) to its directors and officers against loss rising from claims made by reason of breach of duty or other wrongful act, and (b) to the Registrant with respect to payments which may be made by the Registrant to such officers and directors pursuant to the above indemnification provision or otherwise as a matter of law.

     

    The Registrant has entered into indemnification agreements with each of our directors and executive officers. These agreements provide that the Registrant shall hold harmless and indemnify each indemnitee against all expenses and losses actually and reasonably incurred by him or her by reason of the fact that he or she is or was a director, officer, employee or agent of the Registrant, or is or was serving at the request of the Registrant as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, in each case, to the fullest extent permitted under the Delaware General Corporation Law.

     

    3 

     

    Item 8. Exhibits.

     

    Exhibit Number

     
    4.1 Form of Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Registrant’s Amendment No. 1 to Registration Statement on Form S-1, No. 333-248309, filed on September 8, 2020)
    4.2 Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed on July 31, 2024)
    4.3 Form of Bylaws (incorporated by reference to Exhibit 3.2 of the Registrant’s Amendment No. 1 to Registration Statement on Form S-1, No. 333-248309, filed on September 8, 2020)
    4.4 Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 of the Registrant’s Registration Statement on Form S-1, No. 333-248309, filed on August 24, 2020)
    4.5 Second Amended and Restated Investors’ Rights Agreement, dated October 8, 2010, as amended on November 1, 2016, May 29, 2018 and September 5, 2019 (incorporated by reference to Exhibits 4.2, 4.3, 4.4 and 4.5 of the Registrant’s Registration Statement on Form S-1, No. 333-248309, filed on August 24, 2020) and Amendment No. 5 and Joinder to Second Amended and Restated Investors’ Right Agreement, dated September 21, 2020 (incorporated by reference to Exhibit 10.1 of the Registrations Current Report on Form 8-K, No. 001-39515, filed on September 22, 2020)
    5.1* Opinion of Davis Polk & Wardwell LLP
    23.1* Consent of PricewaterhouseCoopers LLP
    23.2* Consent of Davis Polk & Wardwell LLP (included in Exhibit 5.1)
    24.1* Powers of Attorney (included on signature page)
    99.1* 2024 Inducement Plan
    107* Filing Fee Table

     

     

    *Filed herewith.

     

    4 

     

    Item 9. Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement; and

     

    (iii) To include any material information with respect to the Inducement Plan not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    5 

     

    (b) That, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    6 

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant, American Well Corporation, certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on the 4th day of November, 2024.

     

     

    AMERICAN WELL CORPORATION

       
      By: /s/ Ido Schoenberg
        Name: Ido Schoenberg
        Title: Chief Executive Officer

     

    7 

     

    POWER OF ATTORNEY AND SIGNATURES

     

    Know all persons by these presents, that each person whose signature appears below constitutes and appoints Ido Schoenberg, Roy Schoenberg and Bradford Gay, and each of them, as his or her true and lawful attorney-in-fact and agents, upon the action of such appointee, with full power of substitution and resubstitution, to do any and all acts and things and execute, in the name of the undersigned, any and all instruments which each of said attorneys-in-fact and agents may deem necessary or advisable in order to enable American Well Corporation to comply with the Securities Act, and any requirements of the Commission in respect thereof, in connection with the filing with the Commission of this Registration Statement under the Securities Act, including specifically but without limitation, power and authority to sign the name of the undersigned to such Registration Statement, and any amendments to such Registration Statement (including post-effective amendments), and to file the same with all exhibits thereto and other documents in connection therewith, with the Commission, to sign any and all applications, registration statements, notices or other documents necessary or advisable to comply with applicable state securities laws, and to file the same, together with other documents in connection therewith with the appropriate state securities authorities, granting unto each of said attorneys-in-fact and agents full power and authority to do and to perform each and every act and thing requisite or necessary to be done in and about the premises, as fully and to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

     

     

    Signature

    Title

    Date

         
    /s/ Ido Schoenberg, MD Chief Executive Officer November 4, 2024

    Ido Schoenberg, MD

    (Principal Executive Officer and Director) 

         
    /s/ Mark Hirschhorn Chief Financial Officer November 4, 2024

    Mark Hirschhorn

    (Principal Financial Officer)

         
    /s/ Paul McNeice Chief Accounting Officer November 4, 2024

    Paul McNeice


    (Principal Accounting Officer)
        November 4, 2024
    /s/ Roy Schoenberg, MD Executive Vice Chairman
    Roy Schoenberg, MD    
         
    /s/ Dr. Delos (Toby) Cosgrove Director November 4, 2024

    Dr. Delos (Toby) Cosgrove

         
    /s/ Deborah Jackson Director November 4, 2024

    Deborah Jackson

         
    /s/ Ricky Goldwasser Director November 4, 2024

    Ricky Goldwasser

         
    /s/ Derek Ross Director November 4, 2024

    Derek Ross

         
    /s/ Stephen Schlegel Director November 4, 2024

    Stephen Schlegel

         
    /s/ Dr. Peter L. Slavin Director November 4, 2024

    Dr. Peter L. Slavin

         
    /s/ Rob Webb Director November 4, 2024

    Rob Webb

     

    8 

    Get the next $AMWL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMWL

    DatePrice TargetRatingAnalyst
    1/13/2025$15.00Equal Weight → Overweight
    Wells Fargo
    8/3/2023$5.00 → $2.50Overweight → Equal-Weight
    Morgan Stanley
    3/23/2023$5.00 → $2.50Outperform → Market Perform
    TD Cowen
    2/27/2023$5.00 → $3.50Overweight → Neutral
    Piper Sandler
    1/4/2023$4.20Neutral → Buy
    BofA Securities
    9/7/2022$5.00Hold
    Truist
    4/14/2022$6.00Buy
    Guggenheim
    4/1/2022$5.00Neutral
    Credit Suisse
    More analyst ratings

    $AMWL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Product & Tech. Officer Zamansky Dmitry sold $30,279 worth of shares (6,243 units at $4.85), decreasing direct ownership by 3% to 191,468 units (SEC Form 4)

    4 - American Well Corp (0001393584) (Issuer)

    1/5/26 5:09:41 PM ET
    $AMWL
    Real Estate

    President, International Gotlib Phyllis sold $17,979 worth of shares (3,707 units at $4.85), decreasing direct ownership by 3% to 119,870 units (SEC Form 4)

    4 - American Well Corp (0001393584) (Issuer)

    1/5/26 5:04:49 PM ET
    $AMWL
    Real Estate

    Chief Accounting Officer Mcneice Paul Francis sold $1,862 worth of shares (384 units at $4.85), decreasing direct ownership by 11% to 3,063 units (SEC Form 4)

    4 - American Well Corp (0001393584) (Issuer)

    1/5/26 4:58:58 PM ET
    $AMWL
    Real Estate

    $AMWL
    SEC Filings

    View All

    American Well Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - American Well Corp (0001393584) (Filer)

    1/8/26 4:54:17 PM ET
    $AMWL
    Real Estate

    American Well Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - American Well Corp (0001393584) (Filer)

    1/2/26 5:18:14 PM ET
    $AMWL
    Real Estate

    Amendment: SEC Form SCHEDULE 13G/A filed by American Well Corporation

    SCHEDULE 13G/A - American Well Corp (0001393584) (Subject)

    11/14/25 4:19:02 PM ET
    $AMWL
    Real Estate

    $AMWL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Amwell upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Amwell from Equal Weight to Overweight and set a new price target of $15.00

    1/13/25 7:29:38 AM ET
    $AMWL
    Real Estate

    Amwell downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Amwell from Overweight to Equal-Weight and set a new price target of $2.50 from $5.00 previously

    8/3/23 6:19:10 AM ET
    $AMWL
    Real Estate

    Amwell downgraded by TD Cowen with a new price target

    TD Cowen downgraded Amwell from Outperform to Market Perform and set a new price target of $2.50 from $5.00 previously

    3/23/23 7:15:52 AM ET
    $AMWL
    Real Estate

    $AMWL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Amwell® to report fourth quarter and full year 2025 operating results

    BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report fourth quarter and full year 2025 operating results after stock market trading hours on Thursday, Feb. 12. Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The full earnings report and the live audio webcast can be accessed by visiting the Investors section of the company's website. A webcast replay of the call will be available at

    2/5/26 4:05:00 PM ET
    $AMWL
    Real Estate

    Amwell® Announces Results for Third Quarter 2025

    BOSTON , Nov. 04, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced financial results for the third quarter ended September 30. The company's third quarter earnings report may be viewed at investors.amwell.com. Amwell will host a conference call to discuss its financial results today at 5 p.m. ET. The call can be accessed via a live audio webcast at https://edge.media-server.com/mmc/p/63sb3bwu. A webcast replay will be available for approximately 90 days at investors.amwell.com. About Amwell Amwell offers payers and health systems a single, comprehensive, technology-enabled

    11/4/25 4:05:00 PM ET
    $AMWL
    Real Estate

    Amwell® to report third quarter 2025 operating results; company leaders to attend upcoming investor conferences

    BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report third quarter 2025 operating results after stock market trading hours on Tuesday, Nov. 4. Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The full earnings report and the live audio webcast can be accessed by visiting the Investors section of the company's website. A webcast replay of the call will be available at investors.amwell.

    10/27/25 4:35:37 PM ET
    $AMWL
    Real Estate

    $AMWL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by American Well Corporation

    SC 13G/A - American Well Corp (0001393584) (Subject)

    11/12/24 4:43:25 PM ET
    $AMWL
    Real Estate

    SEC Form SC 13G filed by American Well Corporation

    SC 13G - American Well Corp (0001393584) (Subject)

    11/6/24 4:14:27 PM ET
    $AMWL
    Real Estate

    SEC Form SC 13G filed by American Well Corporation

    SC 13G - American Well Corp (0001393584) (Subject)

    11/4/24 11:53:44 AM ET
    $AMWL
    Real Estate

    $AMWL
    Financials

    Live finance-specific insights

    View All

    Amwell® to report fourth quarter and full year 2025 operating results

    BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report fourth quarter and full year 2025 operating results after stock market trading hours on Thursday, Feb. 12. Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The full earnings report and the live audio webcast can be accessed by visiting the Investors section of the company's website. A webcast replay of the call will be available at

    2/5/26 4:05:00 PM ET
    $AMWL
    Real Estate

    Amwell® Announces Results for Third Quarter 2025

    BOSTON , Nov. 04, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced financial results for the third quarter ended September 30. The company's third quarter earnings report may be viewed at investors.amwell.com. Amwell will host a conference call to discuss its financial results today at 5 p.m. ET. The call can be accessed via a live audio webcast at https://edge.media-server.com/mmc/p/63sb3bwu. A webcast replay will be available for approximately 90 days at investors.amwell.com. About Amwell Amwell offers payers and health systems a single, comprehensive, technology-enabled

    11/4/25 4:05:00 PM ET
    $AMWL
    Real Estate

    Amwell® to report third quarter 2025 operating results; company leaders to attend upcoming investor conferences

    BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report third quarter 2025 operating results after stock market trading hours on Tuesday, Nov. 4. Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The full earnings report and the live audio webcast can be accessed by visiting the Investors section of the company's website. A webcast replay of the call will be available at investors.amwell.

    10/27/25 4:35:37 PM ET
    $AMWL
    Real Estate

    $AMWL
    Leadership Updates

    Live Leadership Updates

    View All

    Amwell announces new chief financial officer

    BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital care, today announced Mark Hirschhorn will become Amwell Chief Financial Officer (CFO) effective Oct. 21, succeeding Robert "Bob" Shepardson, who has been in the role since 2021. Hirschhorn will oversee Amwell's financial operations, enterprisewide optimization and capital allocation activities, and will play a meaningful leadership role in guiding the company's strategy to support its long-term growth objectives and enhance shareholder value.   Hirschhorn is a healthcare technology industry leader, with over three decades of experience in financial and strategic operations, having served in senior executiv

    10/15/24 4:30:00 PM ET
    $AMWL
    Real Estate

    Amwell Announces Appointment of Ricky Goldwasser to its Board of Directors

    Boston, June 17, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in hybrid care enablement, today announces the appointment of Ricky Goldwasser to the company's Board of Directors, effective June 13. "Ricky brings to our board a deep financial background that makes her an invaluable addition as we focus on Amwell's path to profitability. Ricky's strong voice coupled with her impressive track record will help guide Amwell as we strive for greater efficiencies, optimized cash flow and profitable growth, while remaining committed to enabling our clients to achieve their goals. We are pleased to welcome Ricky to the team," said Ido Schoenberg, M.D., CEO and chairman, Amwell. Ms. Gol

    6/17/24 8:05:00 AM ET
    $AMWL
    Real Estate

    Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

    ALACHUA, Fla. and TAMPA, Fla., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is pleased to announce today the appointment of Mrs. Kathy Weiler to its Board of Directors, effective December 20, 2023. Weiler, a senior executive with 20+ years of experience and proven track record in driving strategic commercial initiatives, will serve on the Board's Governance, Nominating and Sustainability Committee, and the Quality, Compliance, and Portfolio Management Committee. "I am happy to welcome Kathy to the Board as Axogen is approaching an exciting inflection point in its journ

    12/26/23 4:15:00 PM ET
    $AMWL
    $AXGN
    Real Estate
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care